Relay Therapeutics, Inc. (RLAY)
17.30
+0.24
(+1.41%)
USD |
NASDAQ |
Oct 15, 16:00
17.00
-0.30
(-1.73%)
After-Hours: 04:41
Relay Therapeutics Research and Development Expense (Quarterly) : 76.48M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 76.48M |
| March 31, 2026 | 70.56M |
| December 31, 2025 | 55.42M |
| September 30, 2025 | 68.26M |
| June 30, 2025 | 63.90M |
| March 31, 2025 | 73.81M |
| December 31, 2024 | 68.08M |
| September 30, 2024 | 76.62M |
| June 30, 2024 | 91.99M |
| March 31, 2024 | 82.40M |
| December 31, 2023 | 77.50M |
| September 30, 2023 | 81.49M |
| June 30, 2023 | 88.20M |
| March 31, 2023 | 82.83M |
| December 31, 2022 | 67.28M |
| Date | Value |
|---|---|
| September 30, 2022 | 66.90M |
| June 30, 2022 | 60.51M |
| March 31, 2022 | 51.67M |
| December 31, 2021 | 51.08M |
| September 30, 2021 | 44.17M |
| June 30, 2021 | 44.38M |
| March 31, 2021 | 29.90M |
| December 31, 2020 | 31.42M |
| September 30, 2020 | 23.63M |
| June 30, 2020 | 20.95M |
| March 31, 2020 | 20.99M |
| December 31, 2019 | 21.70M |
| September 30, 2019 | 17.63M |
| June 30, 2019 | 15.81M |
| March 31, 2019 | 12.76M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 6.272M |
| TG Therapeutics, Inc. | 95.34M |
| Karyopharm Therapeutics, Inc. | 28.96M |
| Spyre Therapeutics, Inc. | 65.50M |
| Akebia Therapeutics, Inc. | 13.47M |